# Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.

> **NCT00040157** · PHASE2 · TERMINATED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 60 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** ACH126-443 (Beta-L-Fd4C)

## Key facts

- **NCT ID:** NCT00040157
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2003-05
- **Target enrollment:** 60 (—)
- **Why stopped:** Safety concerns
- **Last updated:** 2015-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00040157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00040157, "Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00040157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*